279 related articles for article (PubMed ID: 31235192)
1. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Grimm MO; Bex A; De Santis M; Ljungberg B; Catto JWF; Rouprêt M; Hussain SA; Bellmunt J; Powles T; Wirth M; Van Poppel H
Eur Urol; 2019 Sep; 76(3):368-380. PubMed ID: 31235192
[TBL] [Abstract][Full Text] [Related]
2. [Side effects of immune checkpoint inhibitor treatment of urological tumors].
Grimm MO; Gottschlich T; Ali N; Foller S; Leucht K
Urologe A; 2021 Jun; 60(6):803-815. PubMed ID: 34100956
[TBL] [Abstract][Full Text] [Related]
3. An update on immunotherapy options for urothelial cancer.
Bilgin B; Sendur MAN; Hizal M; Yalçın B
Expert Opin Biol Ther; 2019 Dec; 19(12):1265-1274. PubMed ID: 31518156
[No Abstract] [Full Text] [Related]
4. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
5. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
6. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
7. Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
Ghatalia P; Plimack ER
J Natl Compr Canc Netw; 2020 Mar; 18(3):355-361. PubMed ID: 32135514
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
Siefker-Radtke A; Curti B
Nat Rev Urol; 2018 Feb; 15(2):112-124. PubMed ID: 29205200
[TBL] [Abstract][Full Text] [Related]
12. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
14. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
[TBL] [Abstract][Full Text] [Related]
15. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
18. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
19. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
20. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]